DUSA Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2009
WILMINGTON, Mass., Nov. 6 /PRNewswire-FirstCall/ — DUSA Pharmaceuticals, Inc.(Ã‚®) (Nasdaq GM: DUSA), a dermatology company that is developing and marketing Levulan(Ã‚®) Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Merriman Curhan Ford Investor Summit 2009 on Tuesday, November 10, 2009 at 10:00 a.m. ET at the Hotel Sofitel in New York City. Interested investors can access the live audio webcast of the presentation at www.dusapharma.com. An archived version of the presentation will be available on the DUSA website for 90 days following the presentation.
About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc.( Ã‚® )is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan(Ã‚®) Photodynamic Therapy technology platform, and complementary dermatology products. Levulan( )PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses of the face and scalp. DUSA also markets other dermatology products, including ClindaReach(Ã‚®). DUSA is researching Levulan PDT for the treatment of AKs and the prevention of new non-melanoma skin cancer in chronically immunosuppressed solid organ transplant recipients. DUSA is based in Wilmington, Mass. Please visit our web site at www.dusapharma.com.
SOURCE DUSA Pharmaceuticals, Inc.